1-7 of 7
Nishanthan Rajakumaraswamy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma

Juan Du, Lina Jin, Sinan Gu, Jing Lu, Haiyan He, Qianqi Ruan, Wanting Qiang, Xiaoqiang Fan, Jin Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Deng Chen, Zonghai Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 3451.
https://doi.org/10.1182/blood-2024-204790
Published: 2024
Journal Articles

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Song Jin, Shuang Yan, Fang Tang, Ziling Zhu, Depei Wu, Ying Li, Nishanthan Rajakumaraswamy, Wei Zheng, Hua Jiang, Zhaohui Liao, Zonghai Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4843.
https://doi.org/10.1182/blood-2024-204401
Published: 2024
Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4762.
https://doi.org/10.1182/blood-2024-204620
Published: 2024
Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Barry Paul, Michaela Liedtke, Jorge Monge, Maria Chaudhry, Robert M. Rifkin, Mitul D. Gandhi, Jack Khouri, Andrew Kin, Tibor Kovacsovics, Moshe Y. Levy, Ann Mohrbacher, William Schmidt, David S. Siegel, Rebecca W. Silbermann, Anna Louise Byrne, Tina Ncube, Michael Murphy, Lin Gu, Nishanthan Rajakumaraswamy, Mark Chao, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2021-145903
Published: 2021
Journal Articles

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Emmanuel Gyan, Maria Chiara Tisi, Francesco Merli, Luca Baldini, Francesco Di Raimondo, Santiago Mercadal, Benedetta Puccini, Elisabeth Vandenberghe, Ka Lung Wu, Anthony Boland, Rikisha Shah Gupta, Anna van Troostenburg, Carolyn Dunnill, Heribert Ramroth, Nishanthan Rajakumaraswamy, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 1350.
https://doi.org/10.1182/blood-2021-146066
Published: 2021
Journal Articles

Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Gilles Salles, MD PhD, Ka Lung Wu, MD PhD, Sofya Kovalchuk, MD, Santiago Mercadal, MD, Annalisa Chiarenza, MD PhD, Ruth Pettengell, MD, Elisabeth Vandenberghe, MD, Paolo Corradini, MD, Susana Carvalho, MD, Christophe De Belder, MSc, Rikisha Shah Gupta, MPH, Anna van Troostenburg, MD, Nishanthan Rajakumaraswamy, MD, Heribert Ramroth, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-137607
Published: 2020
Journal Articles

Matching Adjusted Indirect Comparison to Assess the Relative Efficacy of Idelalisib in Double-Refractory Follicular Lymphoma

Nishanthan Rajakumaraswamy, MBBS, MRCP, FRCA, Eleonora Lovato, MSc, Harry Smith, BSc (Hons), Timothy Bagguley, MSc, Alexandra Smith, PhD, Russell Patmore, FRCPath, Robert Marcus, MB FRCP FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 5842.
https://doi.org/10.1182/blood-2018-99-114473
Published: 2018